⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRNA News
Moderna, Inc. Common Stock
Form 8-K
sec.gov
MRNA
LexisNexis Recognizes Visionary Companies From 18 Countries as “Top 100 Global Innovators” for 2026
globenewswire.com
IBM
ADI
AMAT
AVGO
CDNS
CSCO
DELL
INTC
LRCX
MRVL
MU
NVDA
QCOM
SNPS
TXN
AMD
LLY
MRNA
BMY
GILD
PFE
JNJ
ABBV
AMGN
BIIB
REGN
VRTX
ADSK
GOOG
MSFT
ORCL
CRM
ADPT
ALGN
BKR
CTAS
DDOG
DXCM
EXPE
FIVN
FTNT
IDXX
ILMN
INTU
ISRG
JD
KDP
LULU
MCHP
MDLZ
MELI
MNST
NFLX
NOW
NTES
OKTA
ON
PANW
PAYX
PDD
PEP
PYPL
ROKU
SBUX
SMCI
SWKS
TEAM
TCOM
TDS
TER
TGT
TTEC
TTWO
TWLO
ULTA
VRSK
WDC
WEC
XRAY
ZBRA
ZM
ASML
KLAC
NXPI
AMZN
AAPL
GOOGL
META
TSLA
Z
KHC
CL
PG
COST
WMT
YieldMax® ETFs Announces Weekly Distributions for Group 2 ETFs
globenewswire.com
TSLA
AAPL
NVDA
AMZN
META
GOOGL
NFLX
COIN
MSFT
DIS
XOM
JPM
AMD
PYPL
MRNA
AI
MSTR
SNOW
ABNB
BABA
TSM
SMCI
PLTR
MARA
CVNA
HOOD
BRK.B
DKNG
RBLX
RDDT
GME
HIMS
CRCL
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
globenewswire.com
ABUS
ROIV
MRNA
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
accessnewswire.com
MRNA
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions
businesswire.com
ARDX
MRNA
AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0
globenewswire.com
PFE
MRNA
NVS
MRK
SNY
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
accessnewswire.com
MRNA
YieldMax® ETFs Announces Weekly Distributions for Group 2 ETFs
globenewswire.com
TSLA
AAPL
NVDA
AMZN
META
GOOGL
NFLX
COIN
MSFT
DIS
XOM
JPM
AMD
PYPL
MRNA
AI
MSTR
SNOW
ABNB
BABA
TSM
SMCI
PLTR
MARA
CVNA
HOOD
BRK.B
DKNG
RBLX
RDDT
GME
HIMS
CRCL
RNA-Based Therapeutics & Vaccines Market is projected to reach USD 2.32 Billion by 2032, growing at a CAGR of 5.50% during 2025–2032, Driven by the Rapid Expansion of mRNA Platform Applications: AnalystView Market Insights
globenewswire.com
MRNA
MRK